We asked infectious disease physicians how they learned about the penicillin 56 breakpoint change ( Table 1) . Of the 529 respondents, 82.0% were aware of the 57 breakpoint change at the time of the survey. News reports from IDSA, reports from 58 clinical microbiology laboratories and discussions with colleagues were the most 59 common mechanisms for learning about the breakpoint changes. We asked the physicians 60 how they would prefer to learn of similar breakpoint changes in the future. Preferred 61 mechanisms included IDSA News reports, clinical microbiology laboratory reports, and 62 documents published by CLSI. 63
64
We then asked respondents to consider, given the breakpoint change, how likely 65 they were and how likely they believed non-infectious disease physicians were to use IV 66 penicillin when treating non-penicillin allergic patients with pneumococcal infections. 67
Over half of respondents reported that they were more likely to use IV penicillin (51.2%) 68 while 11.1% reported that they believed non-infectious disease physicians would be more 69 
